BRUKINSA for MCL Approved in Russia
Source: https://unsplash.com/photos/ZHys6xN7sUE

BRUKINSA for MCL Approved in Russia

BRUKINSA (zanubrutinib), an orally administered Bruton's tyrosine kinase (BTK) inhibitor, has been approved in various countries for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma. For…

Continue Reading BRUKINSA for MCL Approved in Russia